[en] The matrix metalloproteinase (MMP) stromelysin-3 (ST3) has been shown to be involved in malignant tumor progression and therefore represents an attractive therapeutical target. In order to screen for ST3 synthetic inhibitors, we have produced and purified the catalytic domain of ST3, matrilysin, stromelysin-2, and membrane type-1 MMP from inclusion bodies in a bacterial system. Our strategy allowed the purification of MMPs directly in the active form, thereby avoidingin vitroactivation. A total of 140,000 synthetic compounds from the Bristol-Myers Pharmaceutical Research Institute chemical deck were tested, using a substrate-based colorimetric enzymatic assay, in which ST3 activity was evaluated through its ability to cleave and inactivate α-1 proteinase inhibitor. One ST3 inhibitor belonging to the cephalosporin family of antibiotics was thereby identified.
Disciplines :
Biochemistry, biophysics & molecular biology
Author, co-author :
Kannan, R.
Ruff, M.
Kochins, J. G.
Manly, S. P.
Stoll, I.
El Fahime, E. M.
Noël, Agnès ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Biologie cellulaire et moléculaire appliquée à l'homme
Foidart, Jean-Michel ; Université de Liège - ULiège > Département des sciences cliniques > Gynécologie - Obstétrique - Labo de biologie des tumeurs et du développement
Dive, v
Basset, P.
Language :
English
Title :
Purification of active matrix metalloproteinase catalytic domains and its use for screening of specific stromelysin-3 inhibitors.
Stöcker, W., and Bode, W. (1995) Structural features of a super-family of zinc-endopeptidases: The metzincins. Curr. Opin. Struct Biol. 5, 383-390.
Coussens, L. M., and Werb, Z. (1996) Matrix metalloproteinases and the development of cancer. Chem. Biol. 3, 895-904.
Basset, P., Okada, A., Chenard, M. P., Kannan, R., Stoll, I., Anglard, P., Bellocq, J. P., and Rio, M. C. (1997) Matrix metalloproteinases as stromal effectors of human carcinoma progression: Therapeutic implications. Matrix Biol. 15, 535-541.
Gomez, D. E., Alonso, D. F., Yoshiji, H., and Thorgeirsson, U. P. (1997) Tissue inhibitors of metalloproteinases: Structure, regulation and biological functions. Eur. J. Cell. Biol. 74, 111-122.
Imren, S., Kohn, D. B., Shimada, H., Blavier, L., and DeClerck, Y. A. (1996) Overexpression of tissue inhibitor of metalloproteinases-2 by retroviral-mediated gene transfer in vivo inhibits tumor growth and invasion. Cancer Res. 56, 2891-2895.
Beckett, R. P. (1996) Recent advances in the field of matrix metalloproteinase inhibitors. Exp. Opin. Ther. Patents 6, 1305-1315.
Stetler Stevenson, W. G., Hewitt, R., and Corcoran, M. (1996) Matrix metalloproteinases and tumor invasion: From correlation and causality to the clinic. Semin. Cancer Biol. 7, 147-154.
Rasmussen, H. S., and McCann, P. P. (1997) Matrix metalloproteinase inhibition as a novel anticancer strategy: A review with a special focus on batimastat and marimastat. Pharmacol. Ther. 75, 69-75.
Rouyer, N., Wolf, C., Chenard, M. P., Rio, M. C., Chambon, P., Bellocq, J. P., and Basset, P. (1995) Stromelysin-3 gene expression in human cancer: An overview. Invasion Metastasis 14, 269-275.
Chenard, M. P., O'Siorain, L., Shering, S., Rouyer, N., Lutz, Y., Wolf, C., Basset, P., Bellocq, J. P., and Duffy, M. J. (1996) High levels of stromelysin-3 correlate with poor prognosis in patients with breast carcinoma. Int. J. Cancer 69, 448-451.
Masson, R., Lefebvre, O., Noël, A., El Fahime, M., Chenard, M.-P., Wendling, C., Kebers, F., LeMeur, M., Dierich, A., Foidart, J.-M., Basset, P., and Rio, M.-C. (1998) In vivo evidence that stromelysin-3 metalloproteinase contributes in a paracrine manner to epithelial cell malignancy. J. Cell Biol. 140, 1535-1541.
Nagase, H. (1997) Activation mechanisms of matrix metalloproteinases. Biol. Chem. 378, 151-160.
Mast, A. E., Enghild, J. J., Nagase, H., Suzuki, K., Pizzo, S. V., and Salvesen, G. (1991) Kinetics and physiological relevance of the inactivation of alpha 1-proteinase inhibitor, alpha 1-antichymotrypsin, and antithrombin III by matrix metalloproteinases-1 (tissue collagenase), -2 (72 -kDa gelatinase/type IV collagenase), and -3 (stromelysin). J. Biol. Chem. 266, 15810-15816.
Pei, D., Majumdar, G., and Weiss, S. J. (1994) Hydrolytic inactivation of a breast carcinoma cell-derived serpin by human stromelysin-3. J. Biol. Chem. 269, 25849-25855.
Noël, A., Santavicca, M., Stoll, I., L'Hoir, C., Staub, A., Murphy, G., Rio, M.-C., and Basset, P. (1995) Identification of structural determinants controlling human and mouse stromelysin-3 proteolytic activities. J. Biol. Chem. 270, 22866-22822.
Wolf, C., Rouyer, N., Lutz, Y., Adida, C., Loriot, M., Bellocq, J. P., Chambon, P., and Basset, P. (1993) Stromelysin 3 belongs to a subgroup of proteinases expressed in breast carcinoma fibroblastic cells and possibly implicated in tumor progression. Proc. Natl. Acad. Sci. USA 90, 1843-1847.
Okada, A., Bellocq, J.-P., Rouyer, N., Chenard, M.-P., Rio, M.-C., Chambon, P., and Basset, P. (1995) Membrane-type matrix metalloproteinase (MT-MMP) gene is expressed in stromal cells of human colon, breast, and head and neck carcinomas. Proc. Natl. Acad. Sci. USA 92, 2730-2734.
Mucha, M., Cuniasse, P., Kannan, R., Beau, F., Yiotakis, A., Basset, P., and Dive, V. (1998) Membrane type-1 matrix metalloprotease and stromelysin-3 cleave more efficiently synthetic substrates containing unusual amino acids in their P′1 positions. J. Biol. Chem. 273, 2763-2768.
DeClerck, Y. A., Yean, T. D., Lu, H. S., Ting, J., and Langley, K. E. (1991) Inhibition of autoproteolytic activation of interstitial procollagenase by recombinant metalloproteinase inhibitor MI/TIMP-2. J. Biol. Chem. 266, 3893-3899.
Knight, G. C., Willenbrock, F., and Murphy, G. (1992) A novel coumarin-labelled peptide for sensitive continuous assays of the matrix metalloproteinases. FEBS Lett. 3, 263-266.
Nagase, H. (1995) Human stromelysins 1 and 2. Methods Enzymol. 248, 449-470.
MacDougall, J. R., and Matrisian, L. M. (1995) Contributions of tumor and stromal matrix metalloproteinases to tumor progression, invasion and metastasis. Cancer Metast Rev. 14, 351-362.
Basset, P., Bellocq, J.-P., Lefebvre, O., Noël, A., Chenard, M.-P., Wolf, C., Anglard, P., and Rio, M.-C. (1997) Stromelysin-3: A paradigm for stroma-derived factors implicated in cancer progression. Crit. Rev. Oncol. Hematol. 26, 43-53.
Barbacid, M. D.-M., Fernandez-Resa, P., Buesa, J.-M., Marquez, G., Aracil, M., Quesada, A. R., and Mira, E. (1998) Expression and purification of human stromelysin 1 and 3 from baculovirus-infected insect cells. Protein Express. Purif. 13, 243-250.
Santavirta, S., Takagi, M., Konttinen, Y. T., Sorsa, T., and Suda, A. (1996) Inhibitory effect of cephalothin on matrix metalloproteinase activity around loose hip prostheses. Antimicrob. Agents Chemother. 40, 244-246.
Thompson, R. W., and Parks, W. C. (1996) Role of matrix metalloproteinases in abdominal aortic aneurysms. Ann. N. Y. Acad. Sci. 800, 157-174.
Grange, J. J., Davis, V., and Baxter, B. T. (1997) Pathogenesis of abdominal aortic aneurysm: An update and look toward the future. Cardivasc. Surg. 5, 256-265.
Hodgson, J. (1995) Remodeling MMPIs. Bio/Technology 13, 554-557.